Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTate & Lyle Regulatory News (TATE)

Share Price Information for Tate & Lyle (TATE)

Share Price is delayed by 15 minutes
Get Live Data
491.40    -13.10 (-2.60%)
Bid:
498.00
Ask:
500.00
Spread: 2.00 (0.402%)
Market Cap: £2.17b
TATE Live PriceLast checked at - London Stock Exchange

Intraday Tate & Lyle Share Chart

Judgment re litigation

29 Sep 2015 14:58

29 September 2015 – Tate & Lyle PLC

Judgment handed down in litigation regarding sale of EU Sugars business in 2010

Tate & Lyle PLC (Tate & Lyle) announces that Judgment was handed down today at the Commercial Court in London in the case brought by American Sugar Refining, Inc. (“ASR”) in which it made a number of claims totalling around £40 million in relation to its acquisition of Tate & Lyle’s EU Sugars business in September 2010 for a consideration of £211 million. The Court found in favour of ASR on two elements of its claims, whilst rejecting all other aspects. Accordingly, in the Judgment, the Court has awarded damages of £18 million (€24.9 million) to ASR (with interest and costs to be determined in due course).

This claim has been disclosed in Tate & Lyle’s Annual Report since 2012 and the expected announcement of this Judgement was highlighted in the Trading Statement on 29 July 2015.

The impact of the Judgment will be reported as an exceptional item within discontinued operations.

END

For more information contact Tate & Lyle PLC:Christopher Marsh, VP, Investor and Media RelationsTel: +44 (0) 20 7257 2110 or Mobile: +44 (0) 7796 192 688

Andrew Lorenz (FTI Consulting), Media RelationsTel: +44 (0) 203 727 1323 or Mobile: +44 (0) 7775 641 807

About Tate & Lyle:

Tate & Lyle is a global provider of ingredients and solutions to the food, beverage and other industries, with operations in over 30 locations worldwide.

Tate & Lyle operates through two global divisions, Speciality Food Ingredients and Bulk Ingredients, supported by our Innovation and Commercial Development and Global Operations groups. The Group's strategy is to become a leading global provider of Speciality Food Ingredients through a disciplined focus on growth, and by driving Bulk Ingredients for sustained cash generation to fuel this growth.

Speciality Food Ingredients consists of three platforms: Texturants, which includes speciality starches and stabilisers; Sweeteners, which comprises nutritive sweeteners and our range of no-calorie sweeteners including SPLENDA® Sucralose; and our Health and Wellness portfolio which includes speciality fibres and our salt-reduction offering. Additionally, our Food Systems business provides a wide variety of blended ingredient solutions.

Tate & Lyle Bulk Ingredients includes bulk sweeteners, industrial starches and fermentation products (primarily acidulants). Corn co-products from both divisions are primarily sold as animal feed.

Tate & Lyle is listed on the London Stock Exchange under the symbol TATE.L. American Depositary Receipts trade under TATYY. In the year to 31 March 2015, Tate & Lyle sales totalled £2.7 billion. For more information, please visit http://www.tateandlyle.com. SPLENDA® is a trademark of Heartland Consumer Products LLC.

View source version on businesswire.com: http://www.businesswire.com/news/home/20150929006222/en/

Copyright Business Wire 2015

Date   Source Headline
25th Jul 20247:00 amRNSTrading Statement
24th Jul 20245:24 pmRNSTransaction in Own Shares
24th Jul 20245:15 pmRNSTotal Voting Rights
23rd Jul 20245:40 pmRNSTransaction in Own Shares
22nd Jul 20245:26 pmRNSTransaction in Own Shares
19th Jul 20245:33 pmRNSTransaction in Own Shares
18th Jul 20245:37 pmRNSTransaction in Own Shares
18th Jul 202410:00 amRNSDirector/PDMR Shareholding
17th Jul 20245:45 pmRNSTransaction in Own Shares
16th Jul 20245:25 pmRNSTransaction in Own Shares
15th Jul 20245:20 pmRNSTransaction in Own Shares
15th Jul 202411:00 amRNSHolding(s) in Company
12th Jul 20245:55 pmRNSTransaction in Own Shares
12th Jul 202411:00 amRNSBlock listing Interim Review
11th Jul 20245:30 pmRNSTransaction in Own Shares
10th Jul 20245:41 pmRNSTransaction in Own Shares
9th Jul 20245:24 pmRNSTransaction in Own Shares
8th Jul 20245:41 pmRNSTransaction in Own Shares
5th Jul 20245:49 pmRNSTransaction in Own Shares
5th Jul 20242:00 pmRNSDirector/PDMR Shareholding
4th Jul 20245:40 pmRNSTransaction in Own Shares
3rd Jul 20245:29 pmRNSTransaction in Own Shares
2nd Jul 20245:32 pmRNSTransaction in Own Shares
2nd Jul 202411:30 amRNSHolding(s) in Company
1st Jul 20245:29 pmRNSTransaction in Own Shares
1st Jul 202412:30 pmRNSTotal Voting Rights
28th Jun 20245:59 pmRNSTransaction in Own Shares
27th Jun 20245:37 pmRNSTransaction in Own Shares
27th Jun 20244:30 pmRNSCompletes sale of remaining interest in Primient
27th Jun 20243:30 pmRNSHolding(s) in Company
26th Jun 20245:38 pmRNSTransaction in Own Shares
25th Jun 20245:50 pmRNSTransaction in Own Shares
24th Jun 20245:35 pmRNSTransaction in Own Shares
24th Jun 20243:30 pmRNSHolding(s) in Company
21st Jun 20245:45 pmRNSTransaction in Own Shares
21st Jun 20242:45 pmRNSUpdate to the Notice of AGM 2024
20th Jun 20246:03 pmRNSTransaction in Own Shares
20th Jun 20247:05 amRNSLaunch of Share Buyback
20th Jun 20247:00 amRNSCombination of Tate & Lyle and CP Kelco
4th Jun 20245:22 pmRNSAnnual Financial Report and Notice of AGM
4th Jun 202411:00 amRNSDirector/PDMR Shareholding
3rd Jun 202412:00 pmRNSTotal Voting Rights
30th May 202412:15 pmRNSHolding(s) in Company
23rd May 20247:00 amRNSFinal Results
23rd May 20247:00 amRNSSale of remaining interest in Primient JV to KPS
20th May 20241:00 pmRNSDirectorate Change
17th May 20243:30 pmRNSHolding(s) in Company
14th May 20243:30 pmRNSHolding(s) in Company
13th May 202410:00 amRNSHolding(s) in Company
8th May 20243:15 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.